From the above evidence, we could therefore comment that both IL-6 and IL-17, being pro-inflammatory, exert pro-tumor effects during later stages of tumor development, which therefore marks that these cytokines, being different, work synergistically to promote progressive events in lung cancer (59, 60). The gene discussed is IL17A; the disease is lung cancer.